We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
GlaxoSmithKline (GSK) is anticipating a second quarter 2007 launch of Flonase follow-on Veramyst pending FDA approval, the company said during its first-quarter earnings call. Read More
Sales of Roche's antiviral Tamiflu are on target to possibly top the $1 billion mark this year, but the company has announced demand from government stockpiling initiatives is winding down. Read More
Bristol-Myers Squibb (BMS) announced a deal under which it may receive up to $1 billion for working with Pfizer to develop and commercialize the anticoagulant apixaban. Read More
A pathway for creating and marketing generic biologics could help health plan sponsors and patients save $71 billion over the next 10 years, according to an Express Scripts report. Read More
Amgen is facing more bad news regarding possible off-label uses of its drug Aranesp, after independent study results pointed to adverse outcomes for a certain class of cancer patients prescribed the drug. Read More
The Dodowa Research Centre in the Dangbe West District of the Greater Accra Region is undergoing a rectal artesunate trial to help reduce death in children under five. Read More
Nurturing slow and steady progress is the key to successful drug development, rather than relying on breakthroughs, according to a report from the Association of the British Pharmaceutical Industry (ABPI). Read More
Cost is preventing a one-of-a-kind vaccine from reaching an estimated 260 children born with HIV daily in South Africa, according to a report by the U.N. Integrated Regional Information Networks (IRIN). Read More
Fewer than half of study coordinators and principal investigators surveyed at a recent institutional review board (IRB) conference said they check whether clinical trial subjects actually understand the informed consent forms (ICFs) they sign, according to an official at BBK Worldwide Read More
Physicians are reevaluating when to initiate therapy with erythropoiesis-stimulating agents (ESAs), Amgen announced during its first-quarter earnings call. Read More